Abstract
P048 - The TRITON clinical trial programme: evaluation of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have